Navigation Links
Fish Oil Supplements Don't Help Depressed Heart Patients

Those who took them with antidepressant fared same as those who didn't

TUESDAY, Oct. 20 (HealthDay News) -- In a surprise and not very welcome finding, researchers report that fish oil supplements do not ease depression in individuals who suffer from both depression and coronary heart disease.

Participants in the study, which is published in the Oct. 21 issue of the Journal of the American Medical Association, were also taking the antidepressant sertraline (Zoloft). Some studies have suggested that the omega-3 fatty acids found in fish might enhance the effects of Zoloft.

"Unfortunately, it's not where we wanted to be. We were kind of disappointed, to say the least," said study author Robert M. Carney, a professor of psychiatry at Washington University School of Medicine in St. Louis.

The findings leave physicians still facing the problem of how to boost depression recovery rates so as to also lower cardiovascular risk. The question is a pressing one, given that depression can double or even triple the risk of dying in heart patients, Carney said.

"We're not just treating depression, we're treating a risk factor," he said.

Fish oil, or omega-3 fatty acid, supplements have been touted as a potential panacea for a variety of ailments, notably heart disease, but they have been losing their luster as of late.

A study published earlier this year found that patients receiving optimal drug therapy after experiencing a heart attack do not gain any additional benefit from taking supplemental omega-3 fatty acids. There was no difference in rates of heart attack, stroke, sudden cardiac death or death from any cause, regardless of whether they were taking the supplements or not.

That finding contradicted previous studies, which suggested that taking omega-3 fatty acids improved long-term survival.

Studies involving omega-3 fatty acids and depression have shown similarly uneven results.

For this study, 122 patients with major depression and coronary heart disease took 50 milligrams of Zoloft a day, then were randomized to receive either 2 grams a day of omega-3 acid ethyl esters or a corn-oil placebo capsule.

There was no difference in depression scores before and after 10 weeks of treatment, the researchers found.

The study authors noted that tweaking any of the variables in the study -- amount of Zoloft, dose of fish oil, form of fish oil or duration of treatment -- might yield more positive results.

In general, the effects of antidepressants in people with both depression and heart problems are the same as in a normal "healthy" population, Carney said.

"The problem, from our point of view, is that that's just not good enough," he added. "It's definitely better than placebo, better than doing nothing. We're trying to find a treatment or combination of treatments that's going to significantly improve the depression outcome."

Had this study turned out more positively, the next step would have been to see if improvements in depression translate into improvements in heart outcomes.

As it is, scientists are back to the drawing board.

"We're still exploring other possibilities," Carney said.

That includes an increased dose of omega-3, lengthening the study and identifying a subset of patients for whom this protocol might be more effective than antidepressants alone.

But it's not time to stop taking fish oil capsules yet, one expert said.

"The American Heart Association still does have recommendations based on the data we do have," said Dr. John Erwin III, professor of internal medicine at Texas A&M Health Science Center College of Medicine, and senior staff cardiologist with Scott & White Hospital in Temple.

"We also use fish oil to reduce triglyceride levels and it's very effective in that use. I wouldn't encourage people who are taking fish oil caplets to stop it now because of this study. It just means we have a little bit more work to do on the depression side of things," he said.

Some of the study authors, including Carney, declared financial ties with different pharmaceutical companies including Pfizer Inc., which makes Zoloft. The study was funded by the U.S. National Heart, Lung, and Blood Institute. GlaxoSmithKline Inc. provided both omega-3 and placebo capsules, while Pfizer supplied the Zoloft.

More information

The U.S. National Library of Medicine has more on omega-3 fatty acids.

SOURCES: Robert M. Carney, Ph.D., professor, psychiatry, Washington University School of Medicine, St. Louis; John Erwin III, M.D., associate professor of internal medicine, Texas A&M Health Science Center College of Medicine, and senior staff cardiologist, Scott & White Hospital, Temple; Oct. 21, 2009, Journal of the American Medical Association

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Chews-4-Health Dietary Supplements to be Featured on 'Beauty Spaces'
2. Valensa to Market Neptune Krill Oil NKO(R) Formulations for Joint Health and Eye Health Dietary Supplements
3. Jerome Bettis Endorses Chews-4-Health Dietary Supplements
4. Swanson Health Products' Vitamin E and Acai Dietary Supplements Pass Quality Control Tests Conducted by
5. Astronauts Test Use of Nutritional Supplements in Space
6. August 2009 Mayo Clinic Health Letter Highlights Herbal Supplements, Groin Rashes and Hand Arthritis
7. Women's Health Expert Dr. Susan Lark Featured on
8. Dr. David Williams Featured on
9. National Council on Skin Cancer Prevention Encourages Americans to Obtain Vitamin D Through Diet and Supplements
10. Board-Certified Cardiologist Dr. Stephen Sinatra Featured on
11. Jillian Michaels, Americas Toughest Trainer, Announces New Line of Weight-Loss Supplements
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: